AOD 9604: Complete Research Guide to Selective Lipolysis and Where to Buy

What Is AOD 9604?

AOD 9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 176–191 of the C-terminus of human growth hormone (hGH), with an additional tyrosine residue added to the N-terminus to stabilize the fragment’s structure. Developed at Monash University by Professor Matthew Vickers, AOD 9604 was designed to retain hGH’s fat-metabolizing (lipolytic) properties while eliminating the anabolic, diabetogenic, and mitogenic effects associated with full-length GH — the latter of which have limited hGH’s therapeutic applicability in metabolic research.

AOD 9604 has attracted substantial research interest for “selective lipolysis” — targeted fat breakdown in adipose tissue without insulin resistance, muscle anabolism, or IGF-1 elevation. Search volume for “aod 9604 peptide” reflects consistent demand from the metabolic research community.

Mechanism of Action

• GH Receptor Binding (Partial): AOD 9604 binds a subregion of the GH receptor (GHR) — specifically the domain responsible for lipolytic signaling — without fully activating the anabolic or proliferative pathways triggered by intact hGH
• β3-Adrenergic Receptor Stimulation: Independent of GHR, AOD 9604 has been shown to stimulate β3-adrenergic receptors on adipocytes, activating hormone-sensitive lipase (HSL) and triglyceride lipase — the enzymes that hydrolyze stored triglycerides
• Selective Adipose Lipolysis: The resulting fatty acid release occurs predominantly in visceral and subcutaneous adipose tissue, not in skeletal muscle — a crucial distinction for body composition research
• No IGF-1 Elevation: Does not stimulate hepatic IGF-1 production at research doses, unlike full-length hGH — enabling cleaner mechanistic studies
• No Insulin Resistance: Does not antagonize insulin signaling at tissue level, a key differentiator from full-length GH
• Anti-Lipogenic Effect: Inhibits acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in de novo lipogenesis (fat synthesis), simultaneously reducing fat storage while increasing fat breakdown

Clinical and Preclinical Research Data

Phase 2 Clinical Trials (TGA-approved in Australia)

• AOD 9604 received TGA (Australian equivalent of FDA) approval for clinical trial use in obesity — a significant regulatory milestone for a research peptide
• Phase 2a trial: Obese adults treated with oral AOD 9604 achieved statistically significant weight loss vs. placebo at 12 weeks
• Phase 2b trial (METAOD): Demonstrated dose-dependent fat mass reduction; 1mg/day showed best benefit-to-tolerability profile
• No diabetogenic effects observed across all dose cohorts — confirming the selective lipolysis hypothesis
• No significant cardiovascular, renal, or hepatic adverse events

Preclinical Obesity Models

• Obese rodents treated with AOD 9604 lost 50% more fat mass over 12 weeks vs. placebo-treated obese controls
• Effect was fat-specific: lean mass preserved, muscle mass unchanged
• Combination with caloric restriction produced additive fat loss effects

Cartilage and Regenerative Research

• Emerging research (largely unpublished commercially) investigates AOD 9604 in cartilage regeneration, particularly osteoarthritis models
• Proposed mechanism: hGH C-terminal domain involvement in chondrocyte differentiation and extracellular matrix synthesis

AOD 9604 vs. HGH Fragment 176-191 — Are They the Same?

Dosage Reference for Research

HPLC Verified

AOD 9604 5mg

Purity: 99%+ HPLC

Format: Lyophilized Powder

Testing: Third-Party COA

$95

Buy Now

HPLC Verified

AOD 9604 10mg

Purity: 99%+ HPLC

Format: Lyophilized Powder

Testing: Third-Party COA

$165

Buy Now

Research Disclaimer: This product is sold strictly for in vitro research and laboratory use only. Not for human consumption. Not medical advice.